Investors Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of unusually large options trading on Wednesday. Stock traders acquired 1,002 put options on the stock. This is an increase of 1,791% compared to the typical volume of 53 put options.

Maravai LifeSciences Stock Performance

Shares of MRVI opened at $1.72 on Thursday. The firm has a market cap of $437.46 million, a price-to-earnings ratio of -1.05 and a beta of 0.18. The company’s fifty day moving average is $2.77 and its 200-day moving average is $4.94. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. Maravai LifeSciences has a 12 month low of $1.68 and a 12 month high of $11.56.

Insider Transactions at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the transaction, the general counsel now owns 167,618 shares in the company, valued at $843,118.54. This trade represents a 12.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in shares of Maravai LifeSciences by 1,172.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock worth $33,658,000 after acquiring an additional 3,731,924 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in Maravai LifeSciences by 145.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company’s stock worth $29,045,000 after purchasing an additional 3,161,072 shares during the period. Marshall Wace LLP grew its holdings in Maravai LifeSciences by 17,912.9% during the fourth quarter. Marshall Wace LLP now owns 2,778,497 shares of the company’s stock valued at $15,143,000 after purchasing an additional 2,763,072 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Maravai LifeSciences by 29.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company’s stock valued at $25,420,000 after purchasing an additional 1,062,485 shares during the period. Finally, CenterBook Partners LP acquired a new stake in shares of Maravai LifeSciences in the fourth quarter worth $4,425,000. 50.25% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on MRVI shares. UBS Group cut their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday, March 21st. Guggenheim initiated coverage on Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating for the company. Baird R W cut Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Robert W. Baird lowered Maravai LifeSciences from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $9.00 to $3.00 in a research report on Wednesday, February 26th. Finally, Morgan Stanley decreased their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of “Hold” and an average price target of $6.34.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.